Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gilead Sciences
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Pfizer
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
AstraZeneca
Hoffmann-La Roche
Pfizer
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
NRG Oncology
H. Lee Moffitt Cancer Center and Research Institute
Mayo Clinic
IDEAYA Biosciences
University of Kentucky
Weill Medical College of Cornell University
Phanes Therapeutics
National Cancer Institute (NCI)
BeiGene
Ohio State University Comprehensive Cancer Center
Prestige Biopharma Limited
NanOlogy, LLC
Bristol-Myers Squibb
Fundación GECP
Fox Chase Cancer Center
EpicentRx, Inc.
Latin American Cooperative Oncology Group
Samsung Bioepis Co., Ltd.
Actuate Therapeutics Inc.
BeiGene
Rutgers, The State University of New Jersey
Humanetics Corporation
Sumitomo Pharma America, Inc.
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Fox Chase Cancer Center
Intergroupe Francophone de Cancerologie Thoracique
Ionis Pharmaceuticals, Inc.
Radiation Therapy Oncology Group
Fox Chase Cancer Center